Printer Friendly
The Free Library
14,799,441 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Akorn Re-States 3rd Quarter Results to Comply With New Guidelines From The SEC And Releases 1998 Year End Results.


BUFFALO GROVE Buffalo Grove

A village of northeast Illinois, a suburb of Chicago. Population: 43,300.
, Ill.--(BUSINESS WIRE)--March 31, 1999--

R & D Expenses for Acquired Assets Now to Be Capitalized

- - - - -

Year End Income Now At $0.25 Per Share

Akorn, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: AKRN) today announced that it has re-stated results ending September 30, 1998 to comply with new guidelines guidelines,
n.pl a set of standards, criteria, or specifications to be used or followed in the performance of certain tasks.
 from the Securities and Exchange Commission (SEC). The impact of this re-statement for the three months ended September 30, 1998 increases net income from $345,000, or $0.02 per diluted di·lute  
tr.v. di·lut·ed, di·lut·ing, di·lutes
1. To make thinner or less concentrated by adding a liquid such as water.

2. To lessen the force, strength, purity, or brilliance of, especially by admixture.
 share, to $1,088,000, or $0.06 per diluted share. Including this adjustment, net income for the year ended December 31, 1998 rose to $4,647,000, or $0.25 per diluted share.

New in-process research and development guidance from the SEC led Akorn to voluntarily capitalize $1,298,000 which the Company had previously expensed in the third quarter of fiscal 1998 as part of the Advanced Remedies, Inc. asset acquisition. The following table documents the impact upon earnings.

Akorn, Inc. manufactures and markets sterile sterile /ster·ile/ (ster´il)
1. unable to produce offspring.

2. aseptic.


ster·ile
adj.
1. Not producing or incapable of producing offspring.

2.
 specialty pharmaceuticals, and markets and distributes an extensive line of ophthalmic ophthalmic /oph·thal·mic/ (of-thal´mik) ocular (1).

oph·thal·mic
adj.
Of or relating to the eye; ocular.


Ophthalmic
Pertaining to the eye.
 surgical supplies and related products. -0-
                        Selected Quarterly Data
               (In Thousands, Except Per Share Amounts)

                                                  Net Income (Loss)

                                               ----------------------
                                                         Per     Per
                                 Net    Gross           Share   Share
                                Sales   Profit  Amount  Basic  Diluted
                               ------- ------- ------- ------- -------
Year Ended December 31, 1998:
  1st Quarter                  $12,051 $ 6,242 $ 1,046  $0.06   $0.06
  2nd Quarter                   13,987   7,021   1,101   0.06    0.06
  3rd Quarter - initial fling   15,138   7,868     345   0.02    0.02
  3rd Quarter - adjustment        --      --       743   0.04    0.04
  3rd Quarter - amended filing  15,138   7,868   1,088   0.06    0.06
  4th Quarter                   15,491   7,929   1,410   0.08    0.08
                               ------- ------- ------- ------- -------
  Full Year                    $56,667 $29,060 $ 4,647  $0.26   $0.25
                               ======= ======= ======= ======= =======


-0-

The information contained in this news release, other than historical information, consists of forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such statements regarding the timing of acquiring and developing new products, of bringing them on line and of deriving revenues and profits from them, as well as the effects of those revenues and profits on the company's margins and financial position, is uncertain because many of the factors affecting the timing of those items are beyond the company's control.

This release, and prior releases, are available on the KCSA KCSA Krannert Center Student Association
KCSA Kentucky Crushed Stone Association (Frankfort, KY)
KCSA Kyiv City State Administration
KCSA Kalamazoo Christian School Association
KCSA Kentucky-Canadian Studies Association
 Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most  Worldwide web site at www.kcsa.com.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 31, 1999
Words:406
Previous Article:Coho Energy Announces Year End Proved Oil and Gas Reserves and Financial Results and Provides Update on Financial Restructuring.
Next Article:Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Files Class Action Suit Against PathoGenesis Corp.
Topics:



Related Articles
Akorn Reports First Quarter Results; Discusses 1998 Outlook.
Akorn, Inc. Announces Withdrawal of Registration Statement.
Akorn, Inc. Reports Record Third Quarter and Nine Months Results.
Akorn Reports Year End and Fourth Quarter Results.
Faruqi & Faruqi, LLP Announces Filing of Class Action Lawsuit Against Akorn, Inc.
Akorn, Inc. Names Marshall L. Goodwin as Vice President, Global Quality and Regulatory Compliance.
Akorn, Inc. Names Russell A. Gall, Vice-President and General Manager, Decatur Operations.
Akorn, Inc. Signs a Letter of Intent with Cipla, Ltd. to Develop and Supply an Oral Anti-Infective ANDA Drug Product.
Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Manufacturing and Supply Agreement For an Oral Anti-Infective ANDA Drug Product.
Akorn Reports First Quarter 2007 Financial Results.(Financial report)

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles